Pharmaceutical Business review

Baron and Budd reaches $177m settlement for seven states against GlaxoSmithKline

This result represents the largest settlement of a pharmaceutical case ever for several of the involved states, and a much higher settlement for each individual state than what they would otherwise have received in a multistate settlement reached in 2012. Baron and Budd attorneys Russell Budd, Burton LeBlanc, Laura Baughman and S. Ann Saucer served in the litigation alongside co-counsel and each state’s Office of the Attorney General.

In the lawsuit, GlaxoSmithKline, the manufacturer of Avandia, was accused of misrepresenting the safety and efficacy of the drug, specifically stating that Avandia reduced adverse cardiac events, when it actually increased them.

Baron and Budd worked with the office of each state’s Attorney General, including Jack Conway, the Attorney General of Kentucky; Doug Gansler, the Attorney General of Maryland; Jim Hood, the Attorney General of Mississippi; Gary King, the Attorney General of New Mexico; Alan Wilson, the Attorney General of South Carolina; Sean Reyes, the Attorney General of Utah; and Patrick Morrisey, the Attorney General of West Virginia.

"These states truly made a wise move to opt out of the nationwide Avandia settlement and, instead, pursue independent litigation," said Russell Budd. "We are honored to have represented them."

With more than 35 years of experience, Baron and Budd has established itself as one of the nation’s leading plaintiffs’ law firms, spearheading meaningful litigation on behalf of consumers. Over the past year, the firm has taken a leadership role in negotiating settlements on behalf of the states of West Virginia, Mississippi and Hawaii regarding the deceptive marketing practices of credit card payment protection plans.

To date, these settlements total more than $21 million. The firm has helped negotiate sweeping national settlements regarding excessive bank overdraft fees, including a $410 million settlement with Bank of America and a $110 million settlement with JPMorgan Chase. Baron and Budd shareholder Burton LeBlanc currently serves on the Plaintiff’s Steering Committee in litigation surrounding GranuFlo, a product used in dialysis and administered at Fresenius Medical Clinics across the country.